(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak - 2Vote in favor of Your Number one tabletop game
- 3Remote telescope farm offers clear views for stargazers
- 4Party Urban communities of the World
- 5Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- Hundreds of Gazans evacuated from Strip for medical treatment - COGAT
- Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
- Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs
- Genome study reveals milestone in history of cat domestication
- Instructions to Warmly greet Certainty and Appeal
- Best Getaway destination: Ocean side, Mountain, or City
- Blood pressure drug recalled for possible cross-contamination
- PA accuses Israel of 'human trafficking' after planeload of Gazans arrives in South Africa
- Drones, physics and rats: Studies show how the people of Rapa Nui made and moved the giant statues – and what caused the island’s deforestation
